Y-Biologics
Seoul
About Y-Biologics
Y-Biologics is specialized in antibody drug since its inception has focused on research and development. They have successfully constructed the unique human antibody library Y-max ABL and new dual antibody platform technology ALiCE. Based on this, they have developed various antibody drugs and become a leading company in the global immuno-chemotherapeutic drug market They are doing their best to leap forward.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $24.9M
- Funding stage: IPO
- Last round: Series Unknown (Feb 2022)
- Ticker: kosdaq:338840
- Website: ybiologics.com
- Phone: + 82-42-867-9971
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/y-biologics-115000 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.